» Articles » PMID: 33817427

Therapy of Ocular Complications in ANCA+ Associated Vasculitis

Overview
Specialty Ophthalmology
Date 2021 Apr 5
PMID 33817427
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

ANCA+ associated vasculitis (AAV) is a group of rare diseases with potentially vision-threatening complications. Ocular and orbital complications of these diseases are caused by vasculitis of the small vessels of the eye or by granulomatous mass formation. ANCA (anti-neutrophil cytoplasmic antibodies) represent a key component of pathophysiological pathways as well as a diagnostic marker. Various manifestations are reported in literature, scleritis and episcleritis being the most common, followed by pseudotumor orbitae. In vision-threatening orbital or ocular disease, aggressive systemic treatment with a combination of high-dose glucocorticoids and either cyclophosphamide or rituximab is needed. Certain cases require locoregional surgical management to preserve ocular integrity or vision. Ocular involvement of AAV remains a challenge in clinical practice, requiring multi-specialty cooperation in order to ensure the best possible visual outcome. AAV = ANCA+ associated vasculitis, ANCA = anti-neutrophil cytoplasmic antibodies, GPA = granulomatosis with polyangiitis, EGPA = eosinophilic granulomatosis with polyangiitis, MPA = microscopic polyangiitis.

Citing Articles

Nodular Scleritis as Isolated Symptom of IgG4-Related Disease, Mimicking as Conjunctival Lymphoma: A Case Report.

Delaisse N, Blockmans D, Van Ginderdeuren R, Missotten G Case Rep Ophthalmol. 2025; 16(1):102-106.

PMID: 39981540 PMC: 11842084. DOI: 10.1159/000543084.


ANCA-associated vasculitis presenting with progressive binocular manifestations: a case report and literature review.

Xi L, Cui Y, Li Z Front Med (Lausanne). 2024; 11:1525111.

PMID: 39722821 PMC: 11668744. DOI: 10.3389/fmed.2024.1525111.


Clinical profile and management of granulomatosis with polyangiitis-associated scleritis from a tertiary care hospital in South India.

Mohanan-Earatt A, Biswas J Indian J Ophthalmol. 2023; 71(1):146-152.

PMID: 36588225 PMC: 10155519. DOI: 10.4103/ijo.IJO_1411_22.


Updates of ocular involvement in granulomatosis with polyangiitis.

Mei L, Wang L, Yan H Graefes Arch Clin Exp Ophthalmol. 2022; 261(6):1515-1523.

PMID: 36473987 DOI: 10.1007/s00417-022-05918-w.


Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Molnar A, Studinger P, Ledo N Front Med (Lausanne). 2022; 9:884188.

PMID: 35721093 PMC: 9205443. DOI: 10.3389/fmed.2022.884188.

References
1.
Csernok E . ANCA testing: the current stage and perspectives. Clin Exp Nephrol. 2012; 17(5):615-618. DOI: 10.1007/s10157-012-0735-y. View

2.
Watts R, Robson J . Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol. 2018; 32(1):3-20. DOI: 10.1016/j.berh.2018.10.003. View

3.
Hinojosa-Azaola A, Garcia-Castro A, Juarez-Flores A, Recillas-Gispert C . Clinical significance of ocular manifestations in granulomatosis with polyangiitis: association with sinonasal involvement and damage. Rheumatol Int. 2019; 39(3):489-495. DOI: 10.1007/s00296-019-04242-7. View

4.
Wilde B, van Paassen P, Witzke O, Cohen Tervaert J . New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2010; 79(6):599-612. DOI: 10.1038/ki.2010.472. View

5.
McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler S . CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. J Rheumatol. 2015; 43(1):97-120. DOI: 10.3899/jrheum.150376. View